



CANNABIS CONTROL COMMISSION

PUBLIC MEETING MINUTES

November 1, 2018 1:00 p.m.
 Health Policy Commission
 50 Milk Street 8th Floor
 Boston, MA

COMMISSION MEMBERS IN ATTENDANCE:

Chairman Steven Hoffman
 Commissioner Kay Doyle
 Commissioner Jen Flanagan
 Commissioner Britte McBride
 Commissioner Shaleen Title

COMMISSION MEMBERS ABSENT: None

LIST OF DOCUMENTS

1. [Presentation from 11/01/2018 Commission Meeting](#)
2. [Executive Summary – Theory Wellness, Inc. – MCN281550 – MPN2811424](#)
3. [Executive Summary – Sanctuary Medicinals, Inc. – MCN281308 – MPN281405](#)
4. [Executive Summary – Gibby’s Garden, LLC – MBN281347](#)
5. [Executive Summary – Ashli’s Farm, Inc. – MRN281332](#)
6. [Executive Summary – Ashli’s Farm, Inc. – MCN281451](#)
7. [Executive Summary – Ashli’s Extract – MPN281374](#)
8. [Final License – Executive Summary – SIRA Naturals – MC281252 – MP281303 – MX281310](#)
9. [Final License – Executive Summary – PharmaCannis-MR281252](#)
10. [Final License – Executive Summary – New England Treatment Access-MC281267-MP281306](#)
11. [Executive Summary – Green Biz – MRN281490](#)
12. [Executive Summary – Temescal Wellness – MCN281550 – MPN281402](#)

Chairman Hoffman called the Cannabis Control Commission to order at 1:01pm on November 1, 2018. Chairman Hoffman put the public on notice that the meeting is being recorded. Chairman Hoffman reviewed the meeting agenda.

Chairman Hoffman turned to the executive director's report. Executive Director Shawn Collins discussed Commission staffing. Mr. Collins introduced Paul Payer, the enforcement counsel and discussed his professional background.

Mr. Collins discussed licensing applications (slide 5). Next, Mr. Collins discussed applications under review by license type (slide 6). Commissioner McBride asked about canopy space and provisional licenses. Mr. Collins discussed the disadvantaged business enterprise statistics (slide 7). Mr. Collins discussed the licensing applications status (slide 8). Mr. Collins discussed the map of applications (slide 9). Mr. Collins discussed total retail applications submitted (slide 10). Mr. Collins discussed agent applications (slide 11). Mr. Collins discussed demographics of agent applications (slide 12 and 13).

Mr. Collins discussed the applications of New England Treatment Access, LLC (#MC281267) and (#MP281306), which staff has recommended for approval of final licensure subject to the conditions set forth in the executive summary. Commissioner Title asked if employee interviews were conducted. Director of Enforcement Patrick Beyea said yes.

Commissioner McBride made a motion to approve (#MC281267), seconded by Commissioner Doyle. The Commission voted 4 in favor (Hoffman, McBride, Doyle, Flanagan) and 1 abstain (Title).

Commissioner Doyle made a motion to approve (#MP281306), seconded by Commissioner McBride. The Commission voted 4 in favor (Hoffman, McBride, Doyle, Flanagan) and 1 abstain (Title).

Mr. Collins discussed the application of Pharmacannis Massachusetts, Inc. (#MR281252), which staff has recommended for approval of final licensure subject to the conditions set forth in the executive summary. Commissioner McBride asked about consumer education materials and operating under the influence. Mr. Beyea said yes. Commissioner Doyle asked about potential change of ownership. Mr. Collins discussed the change in ownership process and stated the Commission had received written assurance from the applicant that there had been no change in ownership executed yet. Commissioner Title asked about change in ownership fee and review of owners from other states. Director of Licensing Kyle Potvin discussed the review process. Commissioner Title noted that she would be continuing to abstain from licensing decisions for licensees that had signed host community agreements she believes went beyond the law.

Commissioner Doyle made a motion to approve, seconded by Commissioner McBride. The Commission voted 4 in favor (Hoffman, McBride, Doyle, Flanagan) and 1 abstain (Title).

Mr. Collins discussed the applications of SIRA Naturals, Inc. (#MC281252), (#MP281303), and (#MX281310), which staff has recommended for approval of final licensure subject to the conditions set forth in the executive summary. Commissioner Doyle asked about potential change of ownership. Mr. Collins discussed the change in ownership process and stated the Commission had received written assurance from the applicant that there had been no change in ownership executed yet. Commissioner Title asked about potential revocation. Chairman

Hoffman asked about the transportation plan. Mr. Beyea discussed the inspection of the vehicles.

Commissioner Doyle made a motion to approve (#MC281252), seconded by Commissioner Flanagan. The Commission voted 4 in favor (Hoffman, McBride, Doyle, Flanagan) and 1 abstain (Title).

Commissioner Doyle made a motion to approve(#MP281303), seconded by Commissioner Flanagan. The Commission voted 4 in favor (Hoffman, McBride, Doyle, Flanagan) and 1 abstain (Title).

Commissioner Doyle made a motion to approve (#MX281310), seconded by Commissioner McBride. The Commission voted 4 in favor (Hoffman, McBride, Doyle, Flanagan) and 1 abstain (Title).

Commissioner McBride inquired about ongoing suitability compliance. Mr. Beyea discussed the compliance process.

Mr. Potvin discussed the applications of Ashli's Extract, Inc. (#MPN281374), (#MCN281451), (#MRN281332), which staff has recommended for approval of provisional licensure subject to the conditions set forth in the executive summary. Commissioner Flanagan asked about ongoing compliance with positive impact plans. Mr. Beyea said routine inspections will be ongoing. Commissioner McBride asked about the products being produced. Commissioner Flanagan discussed her concern about products and diversion. Commissioner Title expressed support for Commissioner McBride and Flanagan's comments and suggested using the review of applications to continue to discuss types of products being produced, any evidence of incidents, and any action that may need to be taken.

Commissioner Title made a motion to approve (#MPN281374), seconded by Commissioner Doyle. The Commission unanimously approved the motion.

Mr. Potvin discussed the application of Ashli's Farm, Inc. (#MCN281451) which staff has recommended for approval of provisional licensure subject to the conditions set forth in the executive summary.

Commissioner Doyle made a motion to approve, seconded by Commissioner McBride. The Commission unanimously approved the motion.

Mr. Potvin discussed the application of Ashli's Inc. (#MRN281332), which staff has recommended for approval of provisional licensure subject to the conditions set forth in the executive summary.

Commissioner Doyle made a motion to approve, seconded by Commissioner Title. The Commission unanimously approved the motion.

Mr. Potvin discussed the application of Gibby's Garden, LLC (#MBN281347), which staff has recommended for approval of provisional licensure subject to the conditions set forth in the

executive summary. Commissioner Title asked if this is the first micro business. Mr. Potvin said yes.

Commissioner McBride made a motion to approve, seconded by Commissioner Doyle. The Commission unanimously approved the motion.

Mr. Collins discussed the application of Green Biz, LLC (#MRN281490), which staff has recommended for approval of provisional licensure subject to the conditions set forth in the executive summary. Commissioner Flanagan put a condition to update the positive impact plan.

Commissioner Doyle made a motion to approve subject to the condition, seconded by Commissioner McBride. The Commission unanimously approved the motion.

Chairman Hoffman adjourned the Commission at 2:23pm. Chairman Hoffman reconvened at 2:40pm.

Mr. Potvin discussed the applications of Sanctuary Medicinals, Inc. (#MCN281308) and (#MPN281405), which staff has recommended for approval of provisional licensure subject to the conditions set forth in the executive summary.

Commissioner Doyle made a motion to approve (#MCN281308), seconded by Commissioner Flanagan. The Commission unanimously approved the motion.

Commissioner Doyle made a motion to approve (#MPN281405), seconded by Commissioner McBride. The Commission unanimously approved the motion.

Mr. Potvin discussed the applications of Temescal Wellness of Massachusetts, Inc. (#MCN281550) and (#MPN281402), which staff has recommended for approval of provisional licensure subject to the conditions set forth in the executive summary. Commissioner Title sat in the audience and recused herself. Commissioner McBride placed a condition to update the positive impact plan.

Commissioner Flanagan made a motion to approve (#MCN281550), seconded by Commissioner Doyle. The Commission unanimously approved the motion. The Commission voted 4 in favor (Hoffman, McBride, Doyle, Flanagan) and 1 recusal (Title).

Commissioner Doyle made a motion to approve subject to the condition (#MPN281402), seconded by Commissioner McBride. The Commission unanimously approved the motion. The Commission voted 4 in favor (Hoffman, McBride, Doyle, Flanagan) and 1 recusal (Title).

Mr. Potvin discussed the applications of Theory Wellness, Inc. (#MCN281524), and (#MPN281424), which staff has recommended for approval of provisional licensure subject to the conditions set forth in the executive summary.

Commissioner Doyle made a motion to approve (#MCN281524), seconded by Commissioner Title. The Commission unanimously approved the motion.

Commissioner Doyle made a motion to approve (#MPN281424), seconded by Commissioner Title. The Commission unanimously approved the motion.

Chairman Hoffman discussed the Commission's code of ethics. Commissioner McBride discussed her edits to the code. Commissioner Title discussed her edits to the code. Commissioner Flanagan thanked the legal team for drafting this. Chairman Hoffman discussed his views on the code of ethics and the social media policy. Commissioner McBride discussed the social media policy section. Commissioner Doyle discussed the duty to report. Commissioner Flanagan discussed unlawful conduct language. Chairman Hoffman said if someone has been charged with a felony, he would like to know. Commissioner Title proposed language under the unlawful conduct section. Commissioner McBride thought misdemeanors should stay in the code. General Counsel Christine Baily said if we cannot come to a consensus, the code will go before the Commission again. Commissioner Doyle would like to have the information if someone is charged. Commissioner Title said she had concerns with reporting a misdemeanor. Commissioner Flanagan noted the Commission asks for disclosure on many issues. Commissioner McBride noted this is a human resources disclosure issue. The Commissioners debated proposed edits. Associate Counsel Pauline Nguyen discussed the code of ethics.

Chairman Hoffman adjourned the Commission at 4:04pm. Chairman Hoffman reconvened the meeting at 4:16pm. The Commissioners continued to debate the code of ethics.

Chairman Hoffman asked for a motion to approve the draft code of ethics, subject to striking section 13C, modify section 15A, and Commissioners Title and McBride's edits and direct the legal department to draft language for Commission consideration relative to social media and the Executive Director to draft a policy on confidentiality. Commissioner Title noted that she does not believe a social media policy is appropriate or necessary. Commissioner Doyle made the motion, seconded by Commissioner Title. The motion is unanimously approved by the Commission.

Chairman Hoffman turned to the summary of the Comments Received for Draft Regulations on Medical Use of Marijuana. Commissioner McBride said she believes changes need to be made to the medical program and have a timeline. Commissioner Title said the Commission needs a date to commit to automatic registration and waiving patient fees, and increasing patient-per-caregiver limits, and raised an issue regarding the architectural review fee. Commissioner Flanagan said the Commission should consider a public education campaign for the medical program.

With unknown business before the Commission, Commissioner Flanagan said she is working on tincture guidance. Chairman Hoffman noted the next public meeting will be November 20, 2018 at 1pm. Chairman Hoffman asked for a motion to adjourn. Commissioner Flanagan made the motion to approve, seconded by Commissioner Doyle. The motion is unanimously approved by the Commission. The Commission is adjourned as of 5pm.

